ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization application for Anktiva. The MHRA will now begin assessing the marketing authorization application for Anktiva in combination with bacillus Calmette-Guerin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, the company said in a statement
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio Approves 2024 Executive Bonuses and New Incentives
- Starbucks reports Q1 beat, Frontier proposes Spirit combination: Morning Buzz
- ImmunityBio enters collaboration with BeiGene on Anktiva trial
- ImmunityBio announces Anktiva MAA accepted for review by EMA
- ImmunityBio initiated with a Buy at BTIG